Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Поражение сердечно-сосудистой системы на фоне терапии лекарственными средствами, влияющими на аппетит и массу тела - Журнал Системные Гипертензии №1 (2010)
Поражение сердечно-сосудистой системы на фоне терапии лекарственными средствами, влияющими на аппетит и массу тела
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В связи с эпидемической заболеваемостью ожирением количество пациентов, принимающих лекарственные препараты для снижения аппетита и уменьшения массы тела, неуклонно растет. В обзоре представлены вопросы классификации препаратов данной группы, необходимые для врача-кардиолога. Представлены патофизиологические механизмы, ведущие к формированию легочной гипертензии и клапанных пороков сердца на фоне приема анорексигенных средств. Приведены данные эпидемиологических и клинических исследований, посвященных этому вопросу.
Ключевые слова: ожирение; средства, уменьшающие аппетит; легочная гипертензия, клапанные пороки.
Keywords: obesity, anorexigenic drugs, pulmonary hypertensions, valvular heart disease.
Ключевые слова: ожирение; средства, уменьшающие аппетит; легочная гипертензия, клапанные пороки.
________________________________________________
Keywords: obesity, anorexigenic drugs, pulmonary hypertensions, valvular heart disease.
Полный текст
Список литературы
1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. 1999–2000. JAMA 2002; 288:1723-7.
2. NHLBI Expert Panel in the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. ObesRes 1998; 6 (Suppl. 2): 51S–2909.
3. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996–1998. Ann Intern Med 2001; 134: 282–6.
4. Wilhelm C. Growing the market for antiobesity drugs. Chemical Market Reporter 2000; FR23–24.
5. Roerig IL, Mitchell JE, de Zwaan M. The eating disorders medicine cabinet revisited: a clinician's guide to appetite suppressants and diuretics. Int J Eat Disord 2003; 33: 443–57.
6. Connolly HM, McGoon M. Obesity drugs and the heart. Curr Prob Cardiol 1999; 24: 745–92.
7. Phentermine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
8. Drug information: appetite esuppressants, sympathomimetics (systemic). http://www.nlm'nih.gov/medlineplus/druginfo/uspdi/202069.html[accessed August 10, 2003].
9. Phentermine. http://www.pdr.net/[accessed December 6, 2003].
10. Fenfluramine and exfenfiuramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
11. Douglas JG, Gough J, Preston PG et al. Long-term efficacy of fenfluramine in treatment of obesity. Lancet 1983; 1: 384–6.
12. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic poten tial in obesity. Drugs 1992; 43: 713–33.
13. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061–6.
14. Mast ST, Gersing KR, Anstrom KJ et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87: 989–93.
15. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51: 642–6.
16. Sibutramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
17. Sibutramine hydrochloride monohydrate. http://www.pdr.net/[accessed December 6, 2003].
18. Petition to the FDA to ban the diet drug sibutramine (Meridia) (HRG Publication#1613). http://www.citizen.org/publications/print_release.cfm>ID=7160 [accessed October 14, 2003].
19. Abbott Laboratories reassures patients of the efficacy and safety of Meridia (sibutramine) and denounces public citizen's petition to the US FDA as in correctand misleading. March 20, 2002. http://www.abbott.com/news/press_release.cfm id=353[accessed December 6, 2003].
20. Bach DS, Rissanen AM, Mendel CM et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363–9.
21. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270–9.
22. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–32.
23. Bupropion Sustained Release Tablets.http://www.pdr.net [accessed December 6, 2003].
24. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48 week double blinded, placebo-controlled trial. Obes Res 2002; 10: 633–41.
25. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33.
26. Topiramate tablets, http://www.pdr.net [accessed December 6, 2003].
27. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
28. Proietto J, Thornburn AW. The therapeutic potential of leptin. Expert Opin lnvestig Drugs 2003; 12: 373–8.
29. Rubin LJ, Barst RJ, Kaiser LR et al. Primary pulmonary hypertension. Chest 1993; 104: 236–50.
30. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985; 27: 160–71.
31. Brenot F, Herve P, Petitpretz P et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537–41.
32. Abenhaim L, Moride Y, Brenot F et al. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16.
33. Mark EJ, Patalas ED, Chang HT et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602–6.
34. Herve P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54.
35. Rothman RB, Redmon B, Raatz SK et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am Cardiol 2000; 85: 913–16.
36. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implication for primary pulmonary hypertension. Circulation 1999; 100: 869–75.
37. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin hypothesis: lessons for the future in pathogenesis. Respir Res 2002; 3: 9–12.
38. Rich S. Primary pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000; 2: 135–40.
39. Rich S, Shillington A, McLaughlin. Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary ulmonary hypertension. Am J Cardiol 2003; 92: 1366–8.
40. Connolly HM, Crary JL, McGoon MD et al. Valvular eart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–8.
41. Kimmel SE, Keane MG, Crary JL et al. Detailed ехamination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999; 84: 304–8.
42. Klein AL, Burstow DJ, Tajik AJ et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3: 54–63.
43. Reid CL, Gardin JM, Yunis C et al. Prevalence and clinic correlated of aortic and mitral regurgitation in a young adult population: the CARDIA Study [Abstract]. Circulation 1994; 90: 1'5–1'9.
44. Jick H, Vasilakis C, Weinrauch LA et al. A population-based study of appetite suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719–24.
45. Khan MA, Herzog CA, St Peter JV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713–8.
46. Weissman N, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, orplacebo. N Engl J Med 1998; 339: 725–32.
47. Wee CC, Phillips RS, Aurigemma G et al. Risk of valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiogra phy before use of medication. Ann Intern Med 1998; 129: 870–4.
48. Jollis JG, Landolfo CK, Kisslo J et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101: 207–7.
49. Burger AJ, Sherman HB, Charlamb MJ et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. Am Coll Cardiol 1999; 34: Ii53–8.
50. Wellman PJ, Maher TJ. Synergistic interactions between fenfluramine and phentermine. Int J Obes 1999; 23: 723–32.
51. Gardin JM, Schumacher D, Constantine G et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703–9.
52. Shively BK, Roldan CA, Gill EA et al. Prevalence and determinants of valvulopathy in patients treated with fexfenfluramine. Circulation 1999; 100: 2161–7.
53. Weissman N, Panza A, Tighe F, Gwynne JT. Natural history of valvu1ar regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 267–73.
54. Gardin JM, Weissman NI, Leung C et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286: 2011–4.
55. Steffee CH, Singh HK, Chitwood WR. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 1999; 8: 245–53.
56. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836–41.
57. Bonow RO, Carabello B, de Leon AC et al. Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association tasks force on practice guidelines. J Am_oll Cardiol 199B; 32: 1486–582.
2. NHLBI Expert Panel in the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. ObesRes 1998; 6 (Suppl. 2): 51S–2909.
3. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996–1998. Ann Intern Med 2001; 134: 282–6.
4. Wilhelm C. Growing the market for antiobesity drugs. Chemical Market Reporter 2000; FR23–24.
5. Roerig IL, Mitchell JE, de Zwaan M. The eating disorders medicine cabinet revisited: a clinician's guide to appetite suppressants and diuretics. Int J Eat Disord 2003; 33: 443–57.
6. Connolly HM, McGoon M. Obesity drugs and the heart. Curr Prob Cardiol 1999; 24: 745–92.
7. Phentermine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
8. Drug information: appetite esuppressants, sympathomimetics (systemic). http://www.nlm'nih.gov/medlineplus/druginfo/uspdi/202069.html[accessed August 10, 2003].
9. Phentermine. http://www.pdr.net/[accessed December 6, 2003].
10. Fenfluramine and exfenfiuramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
11. Douglas JG, Gough J, Preston PG et al. Long-term efficacy of fenfluramine in treatment of obesity. Lancet 1983; 1: 384–6.
12. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic poten tial in obesity. Drugs 1992; 43: 713–33.
13. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061–6.
14. Mast ST, Gersing KR, Anstrom KJ et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87: 989–93.
15. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51: 642–6.
16. Sibutramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
17. Sibutramine hydrochloride monohydrate. http://www.pdr.net/[accessed December 6, 2003].
18. Petition to the FDA to ban the diet drug sibutramine (Meridia) (HRG Publication#1613). http://www.citizen.org/publications/print_release.cfm>ID=7160 [accessed October 14, 2003].
19. Abbott Laboratories reassures patients of the efficacy and safety of Meridia (sibutramine) and denounces public citizen's petition to the US FDA as in correctand misleading. March 20, 2002. http://www.abbott.com/news/press_release.cfm id=353[accessed December 6, 2003].
20. Bach DS, Rissanen AM, Mendel CM et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363–9.
21. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270–9.
22. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–32.
23. Bupropion Sustained Release Tablets.http://www.pdr.net [accessed December 6, 2003].
24. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48 week double blinded, placebo-controlled trial. Obes Res 2002; 10: 633–41.
25. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33.
26. Topiramate tablets, http://www.pdr.net [accessed December 6, 2003].
27. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
28. Proietto J, Thornburn AW. The therapeutic potential of leptin. Expert Opin lnvestig Drugs 2003; 12: 373–8.
29. Rubin LJ, Barst RJ, Kaiser LR et al. Primary pulmonary hypertension. Chest 1993; 104: 236–50.
30. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985; 27: 160–71.
31. Brenot F, Herve P, Petitpretz P et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537–41.
32. Abenhaim L, Moride Y, Brenot F et al. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16.
33. Mark EJ, Patalas ED, Chang HT et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602–6.
34. Herve P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54.
35. Rothman RB, Redmon B, Raatz SK et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am Cardiol 2000; 85: 913–16.
36. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implication for primary pulmonary hypertension. Circulation 1999; 100: 869–75.
37. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin hypothesis: lessons for the future in pathogenesis. Respir Res 2002; 3: 9–12.
38. Rich S. Primary pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000; 2: 135–40.
39. Rich S, Shillington A, McLaughlin. Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary ulmonary hypertension. Am J Cardiol 2003; 92: 1366–8.
40. Connolly HM, Crary JL, McGoon MD et al. Valvular eart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–8.
41. Kimmel SE, Keane MG, Crary JL et al. Detailed ехamination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999; 84: 304–8.
42. Klein AL, Burstow DJ, Tajik AJ et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3: 54–63.
43. Reid CL, Gardin JM, Yunis C et al. Prevalence and clinic correlated of aortic and mitral regurgitation in a young adult population: the CARDIA Study [Abstract]. Circulation 1994; 90: 1'5–1'9.
44. Jick H, Vasilakis C, Weinrauch LA et al. A population-based study of appetite suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719–24.
45. Khan MA, Herzog CA, St Peter JV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713–8.
46. Weissman N, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, orplacebo. N Engl J Med 1998; 339: 725–32.
47. Wee CC, Phillips RS, Aurigemma G et al. Risk of valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiogra phy before use of medication. Ann Intern Med 1998; 129: 870–4.
48. Jollis JG, Landolfo CK, Kisslo J et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101: 207–7.
49. Burger AJ, Sherman HB, Charlamb MJ et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. Am Coll Cardiol 1999; 34: Ii53–8.
50. Wellman PJ, Maher TJ. Synergistic interactions between fenfluramine and phentermine. Int J Obes 1999; 23: 723–32.
51. Gardin JM, Schumacher D, Constantine G et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703–9.
52. Shively BK, Roldan CA, Gill EA et al. Prevalence and determinants of valvulopathy in patients treated with fexfenfluramine. Circulation 1999; 100: 2161–7.
53. Weissman N, Panza A, Tighe F, Gwynne JT. Natural history of valvu1ar regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 267–73.
54. Gardin JM, Weissman NI, Leung C et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286: 2011–4.
55. Steffee CH, Singh HK, Chitwood WR. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 1999; 8: 245–53.
56. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836–41.
57. Bonow RO, Carabello B, de Leon AC et al. Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association tasks force on practice guidelines. J Am_oll Cardiol 199B; 32: 1486–582.
Авторы
И.Е.Чазова, Е.В.Ильина, С.Н.Терещенко
ФГУ РКНПК, ГОУ ВПО МГМСУ
FSI Russian cardiology scientific and production complex, Moscow, Moscow state mediko-stomatologic university
ФГУ РКНПК, ГОУ ВПО МГМСУ
________________________________________________
FSI Russian cardiology scientific and production complex, Moscow, Moscow state mediko-stomatologic university
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.